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Abstract 
The aim of this work is the protection of piroxicam from photodegradation by forming
inclusion complex with 2-hydroxypropyl-β-cyclodextrin. Piroxicam:2-hydroxypropyl-β-
cyclodextrin molecular inclusion complex was prepared by coprecipitation method with 
1:1 molar ratio. Structural characterization of the complex, the corresponding physical
mixture and complexing agents of piroxicam and 2-hydroxypropyl-β-cyclodextrin was car-
ried out by X-ray diffraction (XRD), proton nuclear magnetic resonance (
1H-NMR) and 
Fourier transform infrared spectroscopy (FTIR). Photosensitivity to daylight of piroxicam
and piroxicam:2-hydroxypropyl-β-cyclodextrin inclusion complex was investigated by FTIR. 
The investigations show that higher photostability of piroxicam was achieved in the com-
plex than in non-complexed piroxicam. 
Keywords: inclusion complex, piroxicam, 2-hydroxypropyl-β-cyclodextrin, photodegra-
dation. 
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Piroxicam (4-hydroxy-2-methyl-N-pyrido-2-yl-2H- 
-1,2-benzothiazine-3-carboxamide-1,1-dioxide) is the 
first representative of the class of non-steroidal anti- 
-inflammatory drugs of the oxicam group with anal-
gesic, antipyretic and anti-inflammatory effects. 
Piroxicam shows polymorphism and can exist in 
several conformations [1] and prototrophic shapes [2]. 
Different conformations are proposed for piroxicam in 
the basic state, in accordance with the ability of form-
ing intramolecular hydrogen bonds between the enol 
hydroxyl group and amide carbonyl oxygen [3]. Due to 
zwitterion formation it is found that neutral form is its 
basic state. It is difficult to isolate this behavior spec-
troscopically, so neutral and zwitterionic forms 
together are called “globally neutral” [4]. Excited state 
intramolecular proton transfer (ESIPT) of piroxicam is 
very sensitive to solvent polarity [5]. Acid-base balance 
leads to the existence of different prototrophic forms 
of piroxicam, investigated during the complexation 
with cyclodextrins [6]. Similar spectroscopic behavior 
has been found between piroxicam and one of its pre-
cursors,  i.e., 4-hydroxy-2-methyl-1,2-l-benzothiazine- 
-1,1-dioxide-3-methylcarboxilate, where pyridine ring 
and amide groups are absent [7]. 
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Despite large pharmacological and therapeutic 
potential, piroxicam is hydrophobic and has low solu-
bility in aqueous media, which limits its application. The 
tests showed enhanced release of piroxicam from gra-
nules with β-cyclodextrin [8]. Inclusion complexes of 
piroxicam and β-cyclodextrin can be obtained by vari-
ous methods, such as physical mixing, coprecipitation, 
evaporation and heating under reflux [9,10]. Inclusion 
complex of piroxicam with 2-hydroxypropyl-β-cyclo-
dextrin has a significantly improved solubility [11]. 
Piroxicam can cause skin sensitivity to sunlight and 
therefore is subject to photochemical tests [12–15]. 
The investigations of photostability of drugs and medi-
cinal formulations are very important. Drug photo-
decomposition may result in loss of efficiency and 
development of product side effects due to the form-
ation of photodegradation products during storage or 
use. Photostability depends on the light wavelength, 
intensity and time of exposure. Clinical tests have 
shown that irradiation of piroxicam produces ampiro-
xicam as a photodegradation product, which cannot be 
created by biotransformation of piroxicam [16]. Glass 
et al. have investigated the structure of the resulting 
photodegradation products and photostability of piro-
xicam and other drugs [17]. 
Cyclodextrins and their derivatives are specific drug 
carriers, because of their ability to alter the physical, 
chemical and biological properties of the molecules 
included in their cavities. They have a three-dimen-
sional structure with OH groups on the outside and V.D. NIKOLIĆ et al.: PHOTOSTABILITY OF PIROXICAM  Hem. ind. 68 (1) 107–116 (2014) 
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inside are hydrogen atoms. In an aqueous solution non-
polar aliphatic and aromatic molecules of appropriate 
size may enter the hydrophobic cavities of cyclodex-
trins [18]. As complexing agents they are capable of 
enhancing solubility, photostability, volatility and bio-
availability of various drugs, e.g., nifedipine [19], amlo-
dipin besylate [20], atenolol [21] or allicin [22]. Because 
of better solubility at room temperature than β-cyc-
lodextrin, in this study, 2-hydroxypropyl-β-cyclodextrin 
was chosen (Figure 1). 
The aim of this work is to prepare a molecular 
inclusion complex of piroxicam:2-hydroxypropyl-β-cyc-
lodextrin, to enhance the photostability of piroxicam 
within the complex. The results obtained for the inclu-
sion complex by nuclear magnetic resonance (
1H-NMR), 
X-ray diffraction (XRD) and Fourier transform infrared 
spectrometry (FTIR) were compared with those of phy-
sical mixture of piroxicam and 2-hydroxypropyl-β-cyclo-
dextrin. 
EXPERIMENTAL 
Materials and methods 
Piroxicam was acquired from Megafine Pharma Ltd. 
(99.67% purity), while 2-hydroxypropyl-β-cyclodextrin. 
(97%) was supplied by Merck, Darmstadt. Other sol-
vents and reagents used were p.a. purity. 
Preparation of inclusion complex by co-precipitation 
Piroxicam (1 mmol, 331.348 mg) and 2-hydroxy-
propyl-β-cyclodextrin (1 mmol, 1540 mg) were mixed 
and dissolved in 150 cm
3 of water. The solution was 
mixed at room temperature for 72 h. Due to poor solu-
bility, the prepared solution was then subjected to 
ultrasound. The ultrasound device Sonic, Nis (YU) was 
used and a ultrasonic bath with dimensions A:B:H = 300 
mm×151 mm×200 mm, 8 dm
3 volume, under the fol-
lowing conditions: temperature 30 °C, ultrasound wave 
frequency 40 kHz and power of 150 W, the total nomi-
nal power of 3×50 W and exposure time was 1 h. After 
treatment by ultrasound, this solution was evaporated 
in a vacuum evaporator at 50 °C, protected from the 
light, to volume of approximately 20 cm
3, and then 
dried in a desiccator above concentrated sulfuric acid 
at 25 °C. After drying, a yellow crystalline complex was 
obtained and used for further investigations. 
Preparation of physical mixture 
Physical mixtures were prepared by simple mixing 
of piroxicam with complex agents 2-hydroypropyl-β- 
-cyclodextrin in 1:1 molar ratio. 
Infrared Fourier transformation (FTIR) 
FTIR spectra of samples were recorded in KBr tablet 
(0.2 mg of sample, 140 mg of KBr), wavelength range 
from 4000 to 400 cm
–1 on the FTIR spectrophotometer 
of Bomem Hartmann & Braun MB-series. 
X-Ray crystallography 
X-Ray diffraction was performed on a Phillips PW 
1030 powder diffractometer by exposing the samples 
to monochrome CuKα radiation, λ = 1.54178 Å and 
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analyzed for 2θ (5–45°) with 0.05° increments and 
recording time, τ = 5 s. The voltage and the strength of 
the electric current were 40 kV and 20 mA, respecti-
vely. 
1H-NMR Spectrometry 
1H NMR Spectra of the samples of inclusion complex 
piroxicam:2-hydroxypropyl-β-cyclodextrin, 2-hydroxy-
propyl-β-cyclodextrin and piroxicam were made on a 
Bruker AC 250 E NMR spectrometer with operating 
frequencies of 250 MHz, in a 5 mm diametar glass 
cuvette at room temperature. D2O was used as the 
solvent. 
RESULTS AND DISCUSSION  
Structural characterization of the obtained mole-
cular inclusion complex piroxicam:2-hydroxypropyl-β- 
-cyclodextrin was performed by the methods: X-ray 
diffraction (XRD), proton nuclear magnetic resonance 
(
1H-NMR) and Fourier transform infrared spectroscopy 
(FTIR). 
In Figure 2 given are the diffraction patterns of piro-
xicam, 2-hydroxypropyl-β-cyclodextrin, physical mix-
ture and piroxicam:2-hydroxypropyl-β-cyclodextrin 
molecular inclusion complex. 
High similarity between the diffraction pattern of 
the complex and the diffraction pattern of the 
complexing agent 2-hydroxypropyl-β-cyclodextrin is 
observed in Figure 2. Broad peaks at 11.6 and 18–19° in 
diffractogram of 2-hydroxypropyl-β-cyclodextrin, which 
are not structured, indicate an amorphous structure, 
which is partially retained in the piroxicam:2-hydroxy-
propyl-β-cyclodextrin complex. Piroxicam diffraction 
patterns (Figure 2c) have a number of sharp peaks at 
8.6, 11.8, 14.4, 17.6, 21.6, 25.9 and 27.3° with clearly 
defined reflections, characteristic of an arranged crystal 
structure. Peaks of piroxicam are present in the dif-
fractogram of physical mixtures (Figure 2a), while in the 
diffractogram of the complex (Figure 2b) there are 
none, probably due to the fact that they are protected 
in the cavity of 2-hydroxypropyl-β-cyclodextrin. The 
results of this analysis are consistent with published 
data [11]. 
In order to prove the formation of piroxicam:2- 
-hydroxypropyl-β-cyclodextrin inclusion complex 
1H- 
-NMR analysis was used and the results of these studies 
are presented in Table 1, and the markings of C-atoms 
containing protons of glucopyranose units (A) and 
piroxicam (B) are given in Figure 3. 
1H-NMR spectrum of the piroxicam:2-hydroxypro-
pyl-β-cyclodextrin complex (Table 1), does not give 
signals in the region of chemical shift δ 7.11 to 8.89 
ppm, usually assigned to pyridine and benzene ring of 
piroxicam. On the other hand, present are all typical 
signals of proton from 2-hydroxypropyl-β-cyclodextrin. 
Triplet assigning H3 protons at δ 3.966 and 3.875 ppm 
assigning H6 protons of 2-hydroxypropyl-β-cyclodextrin 
in the complex are shifted towards smaller values of δ 
units by –0.017 and –0.025, respectively. Small shifts in 
 
Figure 2. XRD Diffractograms of physical mixture of 2-hydroxypropyl-β-cyclodextrin and piroxicam (a); piroxicam:2-hydroxypropyl-β-
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the spectra of the complexes indicate that the H3 and 
H6 protons are involved in a noncovalent interaction 
with the guest molecule, piroxicam, i.e., that there was 
an inclusion in the cavity of 2-hydroxypropyl-β-cyc-
lodextrin. 
The FTIR spectra of piroxicam (A), 2-hydroxypropyl-
β-cyclodextrin (B), physical mixture (C) and piroxi-
cam:2-hydroxypropyl-β-cyclodextrin complex (D) are 
shown in Figure 4. 
In the FTIR spectrum of piroxicam (Figure 4A) a 
sharp medium intensity band with a maximum at 3338 
cm
–1 is the result of valence vibrations of OH groups, 
ν(OH), and a low intensity band with a maximum 
absorbance at 3393 cm
–1 corresponds to the valence 
vibration of NH group, secondary amide, ν(NH) [8,23]. 
Absorption bands from the conjugated benzene ring 
and pyridine are located in the range from 1650-1550 
cm
–1 [11]. In the FTIR spectrum of piroxicam (Figure 4A) 
there are bands at 1574 and 1435 cm
–1 originating from 
valence vibrations ν(C=C) of benzene and pyridine. 
Medium intensity absorption band at 1630 cm
–1 is the 
result of valence vibrations ν(C=O) of the secondary 
amides, and the high intensity band at 1530 cm
–1 is the 
result of deformation vibrations of NH group, δ(NH). 
The presence of SO2 group in piroxicam is confirmed by 
bands at 1351 and 1181 cm
–1 originating from the 
asymmetric and symmetric valence vibrations, 
respectively. The area from 660–900 cm
–1 is 
characteristic of deformation vibrations in the plane 
δ(C-H) of aromatic structures, which exist in the 
spectrum of piroxicam, and occur at 875, 830 and 775 
cm
–1. 
The FTIR spectrum of 2-hydroxypropyl-β-cyclo-
dextrin (Figure 4B) is characterized by an intensive 
broad band at 3431 cm
–1, which is the result of OH 
group valence vibrations, ν(OH). In the range of 2970–
2930 cm
–1 expected are the bands from C–H valence 
vibrations that exist in the spectrum, occurring at 2927 
cm
–1. Asymmetric and symmetric C–H deformation vib-
rations in the plane give bands at 1458 and 1374 cm
–1, 
respectively. The complex band (Figure 4B) in the range 
from 1200–1000 cm
–1 with maxima at 1155, 1083 and 
1036 cm
–1 is defined as coupled vibration of C–O, C–O–C, 
C–C–O and C–C–C asymmetric valence vibrations. In 
the range from 700–1000 cm
–1 appear bands of valence 
and deformation vibrations of glukopyranose units. The 
presence of glucopyranose units of 2-hydroxypropyl-β- 
-cyclodextrin in C1 chair conformation is confirmed by 
bands at 950 and 855 cm
–1, which are present in the 
spectrum (Figure 4B). 
Comparative analysis of the FTIR spectra of piroxi-
cam and 2-hydroxypropyl-β-cyclodextrin and the spec-
trum of physical mixtures (Figure 4C) shows the 
Table 1. Chemical shifts (δ) and variations in chemical shifts (Δδ) of protons in 
1H-NMR spectra of piroxicam, 2-hydroxypropyl-β-cyc-
lodextrin and piroxicam:2-hydroxypropyl-β-cyclodextrin complex 
C-atom  δ / ppm (piroxicam)  C-atom 
δ / ppm 
Δδ / ppm 
HP-β-CD Complex 
3' 7.22–8.11  (m, 1H)  1  5.083 (d, 1H)  5.083 (d, 1H)  – 
4' 8.33–8.89  (m, 1H)  2  3.633 (t, 1H)  3.633 (t, 1H)  – 
5 7.22–8.11  (m, 1H)  3  3.966 (t, 1H)  3.959 (t, 1H)  –0.017 
5' 7.11  (t, 1H)  4  3.45–3.53 (m, 1H)  3.45–3.53 (m, 1H)  – 
6 7.22–8.11  (m, 1H)  5  –  –  – 
6' 8.33–8.89  (m, 1H)  6  3.875 (s, 2H)  3.85 (s, 2H)  –0.025 
7 7.22–8.11  (m, 1H)  7  –  –  – 
8 8.18–8.25  (m, 1H)  8  –  –  – 
9 3.00  (s, 3H)  9  1.15 (d, 3H)  1.15 (d, 3H)  – 
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presence of both components, as expected since there 
was no interaction in the mixture. 
FTIR spectrum of piroxicam:2-hydroxypropyl-β-cyc-
lodextrin complex (Figure 4D) was modified in relation 
to the spectra of piroxicam and 2-hydroxypropyl-β-cyc-
lodextrin. In the complex spectrum, intensive band in 
the range of OH group valence vibrations, which occurs 
at 3431 cm
–1 in 2-hydroxypropyl-β-cyclodextrin is 
shifted by 9 units toward the higher values of wave-
length and occurs at 3440 cm
–1. In the same range for 
 
Figure 4. FTIR spectra of piroxicam (A), 2-hydroxypropyl-β-cyclodextrin (B), physical mixture of piroxicam and 
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the complex there are no bands present at 3338 and 
3393 cm
–1, which are characteristic of the ν(OH) and 
ν(NH) of piroxicam. Also, there are no bands in the 
complex indicative of ν(C=C) from the aromatic struc-
tures and bands ν(C=O) from the secondary amide 
groups present in piroxicam. CH valence vibrations, 
which occur at 2927 cm
–1 in the spectrum of 2-hydroxy-
propyl-β-cyclodextrin are shifted towards lower values 
of wavelength in the spectrum of the complex and 
appear at 2925 cm
–1. These shifts may indicate the 
interaction of these groups from 2-hydroxypropyl-β- 
-cyclodextrin with the corresponding groups from piro-
xicam. A band of C–O valence vibrations from 2-hyd-
roxypropyl-β-cyclodextrin at 1155 cm
–1 in the complex 
is shifted to 1150 cm
–1, which also supports the hypo-
thesis of piroxicam inclusion in the cavities of the host. 
C1 conformation of glucopyranose unit of host mole-
cules in the complex is not affected because there are 
bands present at 940 and 853 cm
–1 which are also pre-
sent in the spectrum of 2-hydroxypropyl-β-cyclodex-
trin. 
These studies are consistent with the results of XRD 
and 
1H-NMR analyses and indicate a molecular encap-
sulation of piroxicam. 
Piroxicam is a photosensitive molecule and under 
the influence of light it can degrade whereby the phar-
macological activity and safety of its use are reduced, 
and on the other hand, the adverse effect of the pro-
ducts formed is increased. There are data in the lite-
rature on photostability and possible degradation pro-
ducts of piroxicam [11,17]. Kochevar et al. examined 
the sensitivity of patients to piroxicam photodegra-
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dation products [11], also Glass et al. studied photo-
degradation products (Figure 5) [17]. 
In the process of oxidation the first derivative of 
piroxicam produced is dioxiethane (1), which is con-
verted to carboxylic acid through the ring cleavage (2). 
In transacylation reaction 2-methyl-1,2-benzisothiazol-
3(2H)-one-1,1-dioxide (4) and N-(2-pyridyl)-methoxy-
formylamides (5) are formed. By subsequent carbonyl-
ation of the products (5) N-(2-pyridyl)-methoxyamide 
(6) are produced. The compound N-methyl-N'-(2-pyri-
dyl)-ethane-diamide (3), is obtained by splitting the 
bond between nitrogen and sulfur in the structure (2). 
According to the research literature [17], among the 
resulting photodegradation products the main product 
is 2-methyl-1,2-benziso-thiazol-3(2H)-one-1,1-dioxide (4). 
Stability of piroxicam exposed to daylight was moni-
tored by changes in FTIR spectra for 30 days in our 
investigations. FTIR spectra of piroxicam not exposed to 
light (A) and continuously exposed to daylight for 5 
days (B) are shown in Figure 6. 
In the spectrum of piroxicam which has been 
exposed to daylight for 5 days (Figure 6B) changes in 
the position and intensity of the individual bands can 
be observed in relation to initial piroxicam (Figure 6A). 
OH group (3338 cm
–1) and NH group (3393 cm
–1) 
valence vibration bands in the FTIR spectrum of piro-
xicam which has been exposed to daylight for 5 days 
have a significantly lower intensity and appear in the 
domain of noise. This indicates a change in the 
structure of piroxicam. Also, in the spectrum of piro-
xicam which has been continuously exposed to daylight 
for 5 days (Figure 6B) there is a loss of band at 688 cm
-1 
and a decrease of the band intensity at 734 cm
–1, 
resulting from C–H deformation vibrations outside the 
plane of the aromatic rings. This may indicate a 
degradation of the pyridine ring. On the other hand, 
bands at 1353 and 1182 cm
–1 indicate the presence of 
SO2 group in the piroxicam subjected to photodegrad-
ation. In the degradation product the benzene ring was 
retained as indicated by the bands at 1576 and 1436 
cm
–1 from ν(C=C). The appearance of a new medium 
intensity band at 1600 cm
–1 (Figure 6B) may be 
assigned to a cyclic amide which, depending on the size 
of the ring, can be expected around 1700 cm
–1. Shifting 
of this band towards lower wavelengths can be asso-
ciated with the presence of SO2 group in the cyclic 
amide ring. Based on the above analysis of FTIR spectra 
and the degradation products structure shown [17] it is 
considered that 2-methyl-1,2-benzisothiazol-3(2H)-one- 
-1,1-dioxide (4) had most likely been formed as a deg-
radation product which, according to the literature 
[17], is the most common (60%). 
For determination of piroxicam photostability in the 
complex, FTIR spectroscopy was also applied. In Figure 
 
Figure 6. FTIR spectrum of piroxicam, which has not been exposed (A) and which has been exposed to daylight for 5 days (B).V.D. NIKOLIĆ et al.: PHOTOSTABILITY OF PIROXICAM  Hem. ind. 68 (1) 107–116 (2014) 
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7, A and B are shown the FTIR spectra of piroxicam:2- 
-hydroxypropyl-β-cyclodextrin complexes exposed and 
not exposed to daylight for more than 30 days, respec-
tively. 
Based on the above FTIR spectra (Figure 7A and B) it 
can be noted that piroxicam in the complex is stable 
under the influence of daylight up to 30 days. After this 
period of time the complex begins to decompose as 
evidenced by the change of position, intensity and 
number of bands in its FTIR spectrum (Figure 7B). In 
this spectrum the bands at 1351 and 1081 cm
–1 occur 
as a result of SO2 group valence vibrations, which are 
not present in the initial complex (Figure 7A). The band 
at 1344 cm
–1 (Figure 7A) is not present in a complex 
that has been exposed to daylight for more than 30 
days, but there appeared a band at 1302 cm
–1. There is 
also a band shift from ν(OH) vibrations of the initial 
complex by 26 units toward smaller wavelengths. Band 
occured at 3414 cm
–1 in the spectrum of the complex 
that has been exposed to daylight, which may indicate 
a change in noncovalent interactions within the inclu-
sion complex, i.e., its decomposition. 
The results of this analysis show that the photostab-
ility of piroxicam in the piroxicam:2-hydroxypropyl-β- 
-cyclodextrin inclusion complex is increased compared 
to that of the uncomplexed piroxicam during one 
month of exposure. Therefore, this formulation pro-
tects piroxicam from photodegradation and increases 
the safety of its application. 
CONCLUSIONS 
Molecular inclusion complex of piroxicam with 2-
hydroxypropyl-β-cyclodextrin as complexing agent was 
prepared by coprecipitation method in solid state. 
Complex diffractograms show that the inclusion of 
piroxicam in the cavities of 2-hydroxypropyl-β-cyclo-
dextrin retains the amorphous structure of the com-
plexing agent with the characteristic low intensity 
peaks at 11.6 and 18–19°. Diffraction peaks of piro-
xicam disappear in the diffractogram of the complex, 
indicating its inclusion. Analysis of the results obtained 
by nuclear magnetic resonance (
1H-NMR) indicates that 
the H3 and H6 protons are involved in the noncovalent 
interaction with piroxicam. By analyzing FTIR spectrum 
of the complex piroxicam:2-hydroxypropyl-β-cyclodex-
trin the absence of characteristic peaks of piroxicam is 
observed (valence vibration bands of NH and OH 
groups, aromatic parts of the structure and the secon-
dary amide), and shifts of bands typical of the com-
plexing agent, indicating formation of supramolecular 
structures by inclusion. Testing photostability by FTIR 
method shows that by inclusion of piroxicam in the 
cavities of 2-hydroxypropyl-β-cyclodextrin is protected 
 
Figure 7. FTIR Spectrum of the piroxicam:2-hydroxypropyl-β-cyclodextrin inclusion complex, which has not been exposed to daylight 
(A), and which has been exposed to daylight for 30 days (B).V.D. NIKOLIĆ et al.: PHOTOSTABILITY OF PIROXICAM  Hem. ind. 68 (1) 107–116 (2014) 
 
115 
from daylight for a period of up to 30 days, while piro-
xicam that had not been complexed showed consi-
derably lower stability when exposed to daylight. 
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(Naučni rad) 
Cilj ovog rada je zaštita piroksikama od fotodegradacije formiranjem inklu-
zionog kompleksa sa 2-hidroksipropil-β-ciklodekstrinom. Piroksikam je fotooset-
ljiva supstanca iz grupe nesteroidnih antiinflamatornih lekova. Ciklodekstrini i
njihovi derivati kao specifični nosači mogu lekovitim supstancama da menjaju 
fizičko–hemijska svojstva, tako da je njihova primena aktuelna u farmaceutskoj
industriji. Molekulski inkluzioni kompleks piroksikam:2-hidroksipropil-β-ciklodek-
strin pripremljen je metodom koprecipitacije u molskom odnosu 1:1. Strukturna
karakterizacija kompleksa, odgovarajuće fizičke smeše i kompleksirajućih agenasa
piroksikama i 2-hidroksipropil-β-ciklodekstrina izvršena je difrakcijom rendgenskih
zraka (XRD), protonskom nuklearno magnetnom rezonancom (
1H-NMR) i infracr-
venom spektroskopijom sa Furijeovom (Fourier) transformacijom (FTIR). Pikovi
koji potiču od piroksikama (8,6; 11,8; 14.4º; 17,6; 21,6; 25,9 i 27,3°) nisu prisutni u 
difraktogramu kompleksa piroksikam:2-hidroksipropil-β-ciklodekstrin i ukazuju na 
to da je lek zaklonjen u šupljine domaćina. Da je došlo do kompleksacije pokazuje i
analiza FTIR spektara gde u spektru kompleksa ne postoje trake od valencionih 
vibracija NH i OH grupa, aromatičnih delova strukture i sekundarnog amida pirok-
sikama. 
1H-NMR analiza piroksikama i kompleksa takođe pokazuje da je ostvarena
nekovalentna interakcija pirosikama sa glukopiranoznim jedinicama ciklodekstrina
i da su najveća pomeranja zapažena kod H3 i H6 protona. Fotoosetljivost na dnev-
noj svetlosti za piroksikam i inkluzioni kompleks piroksikam:2-hidroksipropil-β-
-ciklodekstrin ispitivana je metodom FTIR. Rezultati pokazuju da piroksikam koji je
kompleksiran po tipu inkluzije zadržava stabilnost na dnevnu svetlost 30 dana u
odnosu na piroksikam koji nije kompleksiran i koji pokazuje fotostabilnost unutar 
5 dana. Kompleksacijom, piroksikam se štiti od fotodegradacije, čime se obezbe-
đuje sigurnost njegove primene i farmakološka aktivnost.
  Ključne reči: Inkluzioni kompleks • Piro-
ksikam • 2-Hidroksipropil-β-ciklodekstrin 
• Fotodegradacija 
 